Hill Dickinson has advised 4basebio PLC (AIM: 4BB) on an investment by Elevage Medical Technologies (‘Elevage’), a Patient Square Capital platform, and Prudential Assurance Company Limited (acting by its investment manager M&G Investment Management Limited) (‘M&G’). 4basebio is an AIM-listed company which develops and commercialises the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions.
The investment will consist of a £40 million issuance of new shares and the acquisition of £29.4 million of shares from certain existing shareholders. Following completion, Elevage and M&G will together hold 29.9% of 4basebio.
More details on the transaction can be found here.
Corporate partners James Paton-Philip and Francois De Lange, along with senior associate Amy Grosvenor, led the team.
